Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia
This episode discusses enhanced hematopoietic stem cell transplantability. It also covers targeting the JAK-STAT pathway with ruxolitinib for macrophage activation syndrome and refractory anemia, and examines trials on magrolimab for newly diagnosed acute myeloid leukemia.